NCT06854003 2026-02-20
BRAZAN
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06563596 2026-02-19
Epco, Zanu, Ritux for R/R FL or MZL
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06563505 2026-01-21
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05952037 2026-01-02
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
BeOne Medicines
Phase 2 Active not recruiting
NCT06520098 2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2 Recruiting
NCT06549335 2024-10-15
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Ruijin Hospital
Phase 2 Not yet recruiting